JP2023542539A5 - - Google Patents
Info
- Publication number
- JP2023542539A5 JP2023542539A5 JP2023518849A JP2023518849A JP2023542539A5 JP 2023542539 A5 JP2023542539 A5 JP 2023542539A5 JP 2023518849 A JP2023518849 A JP 2023518849A JP 2023518849 A JP2023518849 A JP 2023518849A JP 2023542539 A5 JP2023542539 A5 JP 2023542539A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- human
- mouse
- tumor
- human immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063083016P | 2020-09-24 | 2020-09-24 | |
| US202063083003P | 2020-09-24 | 2020-09-24 | |
| US63/083,003 | 2020-09-24 | ||
| US63/083,016 | 2020-09-24 | ||
| PCT/US2021/051734 WO2022066894A1 (en) | 2020-09-24 | 2021-09-23 | Humanized mouse models for assessing immune cell therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023542539A JP2023542539A (ja) | 2023-10-10 |
| JP2023542539A5 true JP2023542539A5 (cg-RX-API-DMAC7.html) | 2024-07-30 |
Family
ID=80845843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023518849A Pending JP2023542539A (ja) | 2020-09-24 | 2021-09-23 | 免疫細胞療法を評価するためのヒト化マウスモデル |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12196744B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4216971A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023542539A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230074758A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021347320A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3196823A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL301634A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022066894A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11959925B2 (en) | 2017-04-17 | 2024-04-16 | The Jackson Laboratory | Method of determining toxicity of an immunomodulatory drug for use in humans |
| WO2023060126A1 (en) * | 2021-10-06 | 2023-04-13 | Dana-Farber Cancer Institute, Inc. | Engineered cytokine receptors for tunable adoptive cell therapy |
| WO2024029561A1 (ja) * | 2022-08-02 | 2024-02-08 | 学校法人東海大学 | 担がん-免疫不全非ヒト動物、これを用いた供試物質に関するがん免疫応答評価方法 |
| CN117686676B (zh) * | 2023-12-15 | 2025-05-30 | 扬州大学 | 一种基于多水平生物标志物响应法评价水中污染物转代生物效应的方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9100481D0 (en) | 1991-01-10 | 1991-02-20 | Inst Nat Sante Rech Med | Genetically engineered mice |
| US7105158B1 (en) | 1992-11-16 | 2006-09-12 | The Corporation Of Mercer University | Methods of administering microencapsulated materials for immune modulated diseases |
| FR2827302B1 (fr) | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
| WO2006007529A2 (en) | 2004-07-01 | 2006-01-19 | University Of Pittsburgh Of The Commonwealth System For Higher Education | Immunosuppressive exosomes |
| JP2007244268A (ja) | 2006-03-15 | 2007-09-27 | Osaka Prefecture Univ | イヌの造血前駆細胞を認識するモノクローナル抗体の製造方法 |
| EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| CN101715485A (zh) | 2007-04-06 | 2010-05-26 | 国际干细胞公司 | 源于人单性生殖胚泡的患者特异性干细胞系 |
| WO2011036308A1 (en) | 2009-09-28 | 2011-03-31 | Theramab Gmbh | Method for preclinical testing of immunomodulatory drugs |
| EP4502152A3 (en) | 2009-10-06 | 2025-04-30 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| CN102971420B (zh) | 2010-04-14 | 2016-10-26 | 哈伦实验室有限公司 | 无毛nod scid小鼠 |
| EP2422618A1 (en) * | 2010-08-27 | 2012-02-29 | Technologie Integrale Ltd. | Animal model for the evaluation of the efficacy of an HIV vaccine |
| JP2014509841A (ja) | 2011-01-18 | 2014-04-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するための組成物および方法 |
| PT4233537T (pt) | 2011-02-15 | 2025-09-08 | Regeneron Pharma | Ratinhos humanizados para m-csf e utilizações dos mesmos |
| WO2013086019A1 (en) | 2011-12-06 | 2013-06-13 | Massachusetts Institute Of Technology | Use of humanized mice to determine toxicity |
| CN103304669A (zh) | 2012-03-12 | 2013-09-18 | 复旦大学 | 人源化肿瘤免疫细胞因子tntil2及其制备方法和用途 |
| EP4063391A1 (en) | 2012-07-25 | 2022-09-28 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
| DK4389764T3 (da) | 2012-11-05 | 2026-04-13 | Regeneron Pharma | Genetisk modificerede gnavere og fremgangsmåder til anvendelse heraf |
| EP2976641B1 (en) | 2013-03-22 | 2018-01-03 | Imperial Innovations Ltd | In vitro method for assessing cytokine storm responses |
| TWI810145B (zh) * | 2015-06-23 | 2023-08-01 | 杰克森實驗室 | 具有病患衍生之異種移植物之非hla配對的人源化nsg小鼠模式 |
| WO2017040930A2 (en) | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
| CN110099998A (zh) * | 2016-10-26 | 2019-08-06 | 艾欧凡斯生物治疗公司 | 冷冻保存的肿瘤浸润淋巴细胞的再刺激 |
| WO2018102546A1 (en) | 2016-11-30 | 2018-06-07 | The Jackson Laboratory | Humanized mouse model with improved human innate immune cell development |
| US11959925B2 (en) | 2017-04-17 | 2024-04-16 | The Jackson Laboratory | Method of determining toxicity of an immunomodulatory drug for use in humans |
| US11778994B2 (en) * | 2017-05-12 | 2023-10-10 | The Jackson Laboratory | NSG mice lacking MHC class I and class II |
| US20190091310A1 (en) * | 2017-09-26 | 2019-03-28 | Stephen E. Wright | Nonreleased il-12 for therapy of cancer |
| US11712026B2 (en) | 2017-10-18 | 2023-08-01 | The Jackson Laboratory | Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development |
| WO2019084018A1 (en) * | 2017-10-23 | 2019-05-02 | City Of Hope | CAR FOR THE TREATMENT OF HIV INFECTION |
| CN110055223A (zh) * | 2018-01-19 | 2019-07-26 | 北京百奥赛图基因生物技术有限公司 | 一种B2m基因改造的免疫缺陷动物的制备方法及其应用 |
| US20210214723A1 (en) * | 2018-06-01 | 2021-07-15 | Mayo Foundation For Medical Education And Research | Materials and methods for treating cancer |
| WO2020206149A2 (en) * | 2019-04-05 | 2020-10-08 | The Regents Of The University Of California | Methods and compositions involving chimeric binding polypeptides |
-
2021
- 2021-09-23 AU AU2021347320A patent/AU2021347320A1/en active Pending
- 2021-09-23 IL IL301634A patent/IL301634A/en unknown
- 2021-09-23 CA CA3196823A patent/CA3196823A1/en active Pending
- 2021-09-23 JP JP2023518849A patent/JP2023542539A/ja active Pending
- 2021-09-23 KR KR1020237013626A patent/KR20230074758A/ko active Pending
- 2021-09-23 WO PCT/US2021/051734 patent/WO2022066894A1/en not_active Ceased
- 2021-09-23 EP EP21873419.2A patent/EP4216971A4/en active Pending
-
2022
- 2022-03-25 US US17/705,037 patent/US12196744B2/en active Active
-
2024
- 2024-12-06 US US18/972,072 patent/US20250164467A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhong et al. | Cytokines and chemokines in HBV infection | |
| Dorner et al. | Coordinate expression of cytokines and chemokines by NK cells during murine cytomegalovirus infection | |
| Barnes et al. | Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. | |
| Skinnider et al. | The role of interleukin 13 in classical Hodgkin lymphoma | |
| Hillinger et al. | EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-γ-dependent antitumor responses in a lung cancer model | |
| Smith et al. | Production of interleukin-10 by human bronchogenic carcinoma | |
| Curtsinger et al. | Autocrine IFN-γ promotes naive CD8 T cell differentiation and synergizes with IFN-α to stimulate strong function | |
| Yoo et al. | IL-18 induces monocyte chemotactic protein-1 production in macrophages through the phosphatidylinositol 3-kinase/Akt and MEK/ERK1/2 pathways | |
| Kitaya et al. | Spatial and temporal expression of ligands for CXCR3 and CXCR4 in human endometrium | |
| Fisman et al. | Cardiovascular diabetology in the core of a novel interleukins classification: the bad, the good and the aloof | |
| Sharma et al. | Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma | |
| Lingnau et al. | IL-4 in combination with TGF-β favors an alternative pathway of Th1 development independent of IL-12 | |
| Wang et al. | Cytokines frequently implicated in myeloproliferative neoplasms | |
| Punnonen et al. | Cytokine production profiles in the peritoneal fluids of patients with malignant or benign gynecologic tumors | |
| Zhang et al. | Cytokine storm and targeted therapy in hemophagocytic lymphohistiocytosis | |
| JP2019536457A5 (cg-RX-API-DMAC7.html) | ||
| Sotnikova et al. | Cytokine network of eutopic and ectopic endometrium in women with adenomyosis | |
| Schmidt et al. | IL-17 receptor C signaling controls CD4+ TH17 immune responses and tissue injury in immune-mediated kidney diseases | |
| Rosati et al. | Rapid transient and longer-lasting innate cytokine changes associated with adaptive immunity after repeated SARS-CoV-2 BNT162b2 mRNA vaccinations | |
| Trümper et al. | Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease | |
| Nath et al. | Macrophage inflammatory protein (MIP) 1 α and MIP1 β differentially regulate release of inflammatory cytokines and generation of tumoricidal monocytes in malignancy | |
| Mikita et al. | Recent advances in cytokines in cutaneous and systemic lupus erythematosus | |
| Hou et al. | Rapid downregulation of programmed death‐1 and interferon‐γ‐inducible protein‐10 expression is associated with favourable outcome during antiviral treatment of chronic hepatitis B | |
| Kennedy et al. | Role of chemokines in the regulation of Th1/Th2 and autoimmune encephalomyelitis | |
| Zhao et al. | Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer |